JKDA 2020; 3(1): 9-11
Published online May 25, 2020
© Korean Society of Dialysis Access
전흥만
인제대학교 일산백병원 외과
Correspondence to : 전흥만
우 10380, 고양시 일산서구 주화로 170, 인제대학교 일산백병원 외과
Tel: 031-910-7947, Fax: 031-910-7782, E-mail: junh@paik.ac.kr
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Many patients who use hemodialysis for end-stage renal disease (ESRD) require arteriovenous fistula (AVF). There have been many efforts including preoperative and postoperative access surveillance to improve the primary patency after AVF. Several drugs have been proposed to improve AVF patency based on anticoagulants, antiplatelets or antihypertensives. However, there is little evidence to guide the drug strategy. This review did not show a beneficial effect on the treatment of any adjuvant that increases the patency of AVF, except for ticlopidine and calcium channel blockers.
Keywords Medical adjuvant treatment, Arteriovenous fistula, Patency
JKDA 2020; 3(1): 9-11
Published online May 25, 2020
Copyright © Korean Society of Dialysis Access.
전흥만
인제대학교 일산백병원 외과
Heungman Jun
Department of Surgery, Ilsan Paik Hospital, Inje University College of Medicine, Goyang, Korea
Correspondence to:전흥만
우 10380, 고양시 일산서구 주화로 170, 인제대학교 일산백병원 외과
Tel: 031-910-7947, Fax: 031-910-7782, E-mail: junh@paik.ac.kr
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Many patients who use hemodialysis for end-stage renal disease (ESRD) require arteriovenous fistula (AVF). There have been many efforts including preoperative and postoperative access surveillance to improve the primary patency after AVF. Several drugs have been proposed to improve AVF patency based on anticoagulants, antiplatelets or antihypertensives. However, there is little evidence to guide the drug strategy. This review did not show a beneficial effect on the treatment of any adjuvant that increases the patency of AVF, except for ticlopidine and calcium channel blockers.
Keywords: Medical adjuvant treatment, Arteriovenous fistula, Patency
Chanyeong Park, Suyoung Park
JKDA 2024; 7(2): 45-48 https://doi.org/10.56774/jkda24008Minsu Noh, Sang Jun Park, Hojong Park
JKDA 2024; 7(1): 12-18 https://doi.org/10.56774/jkda23012Jeeyoung Min, Sang Woo Park, Jin Ho Hwang
JKDA 2024; 7(1): 9-11 https://doi.org/10.56774/jkda24006